Short Reads

Product liability under Directive 85/374: a potential defect, is a defect too

Product liability under Directive 85/374: a potential defect, is a defect too

Product liability under Directive 85/374: a potential defect, is a defect too

02.12.2015 NL law

In its decision of 5 March 2015 (joined cases C-503/13 and C-504/13), in reply to preliminary questions of the German Bundesgerichtshof, the European Court of Justice (ECJ) clarified that under Directive 85/374 an implantable medical device can be considered defective for the mere reason that the product belongs to a group or series of products that has a potential risk of being defective. If the product belongs to that group or series of products, there is no need to establish that the individual product actually suffers from that defect as well.

In 2005, Boston Scientific, a producer of medical devices, found that a particular type of pacemaker it produced had a substantially higher chance of being defective than normal according to its own standards. As a result, Boston Scientific recommended that physicians replace the pacemakers, which would be provided free of charge. Around the same time, Boston Scientific also found that a particular type of implantable cardioverter defibrillator might be affected by a defect as well. Therefore, Boston Scientific recommended that physicians mitigate the consequences of such potential defect by deactivating a certain switch of the implantable cardioverter defibrillator.

Although the pacemakers were free of charge and the implantable cardioverter defibrillator did not need to be replaced, the patients (or their health insurers) still incurred  the costs of the surgery and hospital stay. For this reason, two of the health insurers (AOK Sachsen-Anhalt-Gesundheidskasse and Betriebskrankenkasse RWE) involved decided to seek recourse against Boston Scientific for damages for death and personal injury under article 9(1) of the Directive, as transposed into German product liability law.

During the legal proceedings before the German courts, Boston Scientific disputed that the pacemakers and implantable cardioverter defibrillators involved were defective.

Under article 4 of the Directive, the burden of proving the defect, the damage and the causal relationship between defect and damage lies with the injured person and, following subrogation, with their health insurers. As the pacemakers were destroyed after their removal without any expert examination, the health insurers would have severe difficulties in proving any defect. After all, these pacemakers and the implantable cardioverter defibrillator were not removed because they had a defect, they were removed because the possibility  of these devices having a defect was higher than normal according to Boston Scientific’s standards.

After the health insurers won the case before the German courts in two instances, the German Bundesgerichtshof decided to ask the ECJ preliminary questions about – in short – the interpretation of the notions of “defect” and “death and personal injury” under the Directive, in the context of this case.

The ECJ ruled that to establish whether a product is defective, according to article 6(1) of the Directive, all circumstances must be taken into account including the presentation of the product, how it could reasonably be expected to be used and when it was put into circulation. The safety one may expect from a product is to be established by considering the purpose of the product. Given the purpose and in light of the particularly vulnerable situation of the patients using pacemakers and implantable cardioverter defibrillators, the ECJ stated that the safety requirements for these devices, which such patients are entitled to, are particularly high.

The potential lack of safety which would give rise to liability of the producer under the Directive, for this type of product, stems from the abnormal potential for damage which those products might cause to the person concerned. If the products involved belong to the same group or form part of the same production series that have a potential defect, it is possible to classify all the products of that group or series as defective without there being any need to prove that the individual product is defective as well. If and in so far as surgery and hospital stay is necessary to overcome the defect in that device in the product in question, the ECJ considers these costs damage caused by death or personal injury to be borne by the producer.

As a consequence of this decision, producers must be aware that, depending on the nature of their product, under certain circumstances they may need to compensate consumers for damages following a product recall, even where the individual products may not be defective.

In the Netherlands, it is less likely that health insurers will be able to successfully claim damages on the basis of Directive 85/374 in a similar case. Article 1 of the Directive is transposed into Dutch law by means of article 6:185 Dutch Civil Code (DCC) (liability for defective products). Under Dutch law (article 6:197 DCC), a Dutch insurer that has paid out the insurance proceeds to the person insured having recourse against the producer of defective products under article 6:185 DCC is explicitly excluded.

However, Dutch health insurers may be entitled to claim damages under article 6:162 DCC (liability for an unlawful act). In the event of a claim based on article 6:162 DCC, the health insurer has to prove that the producer of the device has committed an attributable unlawful act which has resulted in damages. This makes the threshold for a successful claim for damages on the basis of article 6:162 DCC, possibly higher than for a claim under 6:185 DCC.

The post Product liability under Directive 85/374: a potential defect, is a defect too is a post of stibbeblog.nl

Team

Related news

12.02.2020 EU law
Dutch court rules that investors suffer investment loss in the market where securities are listed and traded

Short Reads - On 29 January 2020, the Rotterdam District Court ruled on the question of which laws are applicable to the tort claims brought by (former) Petrobras investors against Petrobras (ECLI:NL:RBROT:2020:614). The Court applied the main rule of EU Regulation Rome II (the “Rome II Regulation”), which stipulates that the law applicable to claims in tort is the law of the country in which the harm suffered by the victim as a result of the tort occurs.

Read more

06.02.2020 NL law
Wettelijke bedenktijd door het bestuur van een beursvennootschap

Short Reads - Op 23 december 2019 is het wetsvoorstel tot wijziging van Boek 2 van het Burgerlijk Wetboek in verband met het inroepen van een bedenktijd door het bestuur van een beursvennootschap bij de Tweede Kamer ingediend. Dit wetsvoorstel volgt op een consultatie over het voorontwerp die liep van 7 juli 2018 tot en met 7 februari 2019.

Read more

16.01.2020 NL law
Wetgever, koester het burgerlijk procesrecht

Articles - Civiele procedures worden waarschijnlijk niet sneller en eenvoudiger met het Conceptwetsvoorstel modernisering en vereenvoudiging bewijsrecht en de Tijdelijke Experimentenwet rechtspleging. De wetsvoorstellen gaan uit van onjuiste veronderstellingen over het verloop van civielrechtelijke procedures en overspannen verwachtingen van de rol van de civiele rechter als alvermogende geschilbeslechter.

Read more

15.01.2020 NL law
The Dutch scheme - a summary of the upcoming new restructuring tool

Short Reads - As mentioned in our earlier blog, the Dutch legislator has prepared a bill – the Act on confirmation of private restructuring plans (Wet homologatie onderhands akkoord) – introducing a framework that allows debtors to restructure their debts outside formal insolvency proceedings (the “Dutch Scheme“). We expect this highly-anticipated bill to enter into force by this summer. The Dutch Scheme combines features from the UK Scheme of Arrangement and the US Chapter 11 proceedings. Below, we summarize certain key aspects of the Dutch Scheme.

Read more

This website uses cookies. Some of these cookies are essential for the technical functioning of our website and you cannot disable these cookies if you want to read our website. We also use functional cookies to ensure the website functions properly and analytical cookies to personalise content and to analyse our traffic. You can either accept or refuse these functional and analytical cookies.

Privacy – en cookieverklaring